News

An antibody used to treat the autoimmune skin disease psoriasis is also effective at reducing aortic inflammation, a key marker of future risk of major cardiovascular events.

Emery N. Brown explains how statistics and neuroscience improve anesthesiology at the American Association for the Advancement of Science's annual meeting.

Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or disease. Now, a study in mice suggests another use for iPS cells: training the immune system to attack or even prevent tumors.

Absolute Antibody Ltd., and Kerafast Inc., have announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.

ImmunoQure, a biotech company focused on the research and development of human autoantibodies as therapeutics for the treatment of common human diseases and the international pharmaceutical company Servier today announced the establishment of a Worldwide, exclusive partnership for the development of a therapeutic autoantibody neutralizing interferon-alpha.

In the largest study to date on children in a low/middle income country, research finds that the timing of a measles vaccine in an overall vaccination schedule can have a profound impact on child survival rates beyond protecting against measles infection.

Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.

Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug.

New research could help to safely adapt a new immunotherapy - currently only effective in blood cancers - for the treatment of solid cancers, such as notoriously hard-to-treat brain tumours.

Engineered AAV strain efficiently enters the brain to deliver its therapeutic payload.